Weight loss jabs such as Mounjaro linked to lower dementia and stroke risk
Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'.
People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found.
The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity.
Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. https://t.co/WhHodrztS1 pic.twitter.com/Rll5Eg3ycU
— Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025
Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic.
GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed.
The other half used other anti-diabetic medication.
📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: https://t.co/ml4QJgZ224 pic.twitter.com/uURpuIuYzx
— NHS Dorset (@NHSDorset) June 23, 2025
During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke.
They were also 30% less likely to die during the follow-up period.
And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40.
They found no differences in Parkinson's disease or brain bleeds.
The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings.
Recommended reading:
Mounjaro sales adverts banned by watchdog
Mounjaro patients report unexpected side-effect
Who is eligible for free Mounjaro on the NHS?
'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open.
Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Recommended reading:
When will Mounjaro be rolled out on the NHS?
Travel insurance warning about certain types of policy
Warning as Mounjaro and Ozempic sold without prescription
Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia.
'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity.
'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear.
'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis
LILLE, France & PARIS--(BUSINESS WIRE)--4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. 'Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,' said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. 'Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. By acting directly in the joint, 4P004 tackles pain, inflammation, and tissue damage through GLP-1-mediated pathways. We believe its targeted intra-articular delivery can unlock the full therapeutic power of GLP-1 biology. We are eager to confirm both symptomatic relief and meaningful structural benefit in this proof-of-concept study'. The study's primary endpoint is the reduction in knee pain at week 4 and 12. Key secondary objectives include assessing synovial changes by contrast-enhanced MRI and conducting an exploratory analysis of blood and imaging biomarkers as potential surrogates for long-term disease progression and delay to total knee replacement. The study timeline covers 12 months, with patient enrollment taking place over 9 months and follow-up to be completed before the topline readout in the second half of 2026. INFLAM MOTION has been designed to generate the first human evidence that 4P004 can deliver both clinical relief and measurable structural benefit. Insights from this Phase 2a readout will shape the forthcoming Phase 2b program, whose primary aim will be to confirm surrogate endpoints that reliably predict the hard endpoint that is delaying the time to total knee replacement. About 4MB Incorporated in mid-2020 as a spin-off of 4P-Pharma, 4MB is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France. Website: LinkedIn: The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
Yahoo
7 hours ago
- Yahoo
Physician associates ‘should be banned from seeing patients without review'
Physician associates (PAs) should be banned from seeing patients who have not been reviewed by a medic to prevent the risk of 'catastrophic' misdiagnoses, a Government-ordered report has found. The study suggests a major change to the role of PAs after it acknowledged they have been used as substitutes for doctors, despite having significantly less training. More than 3,500 PAs and 100 anaesthesia associates (AAs) are working in the NHS and there have been previous calls for an expansion in their number. But a general lack of support for the roles from the medical profession – plus high-profile deaths of patients who were misdiagnosed by PAs – led Health Secretary Wes Streeting to order a review. Presenting her findings, Professor Gillian Leng, president of the Royal Society of Medicine, said: 'Crucially I'm recommending that PAs should not see undifferentiated or untriaged patients. 'If (patients) are triaged, they (PAs) should be able to see adult patients with minor ailments in line with relevant guidance from the Royal College of GPs.' She said more detail was needed on which patients can be seen by PAs and national clinical protocols should be developed in this area. She added: 'Let's be clear, (the role of PAs) is working well in some places, but there indeed has been some substitution and any substitution is clearly risky and confusing for patients.' Prof Leng also recommended PAs should be renamed 'physician assistants' to position them 'as a supportive, complementary member of the medical team', while AAs should be renamed 'physician assistants in anaesthesia'. Newly qualified PAs should also work in hospitals for two years before they are allowed to work in GP surgeries or mental health trusts. The study said safety concerns in relation to PAs were 'almost always about making a diagnosis and deciding the initial treatment, particularly in primary care or the emergency department, where patients first present with new symptoms.' It added: 'It is here that the risk of missing an unusual disease or condition is highest, and where the more extensive training of doctors across a breadth of specialties is important. 'Making the wrong initial diagnosis and putting patients on an inappropriate pathway can be catastrophic.' Despite the shorter two years of training for PAs, where local NHS services have struggled with filling roles, 'the easy option in some cases was simply to fill gaps in medical rotas with PAs', the report went on. 'This seems to have been done without taking into account the more limited training of the PAs and how the roles would interact, other than with the caveat that they would be supervised by doctors. 'This lack of planning may have been responsible for driving the resentment felt by some resident (doctors) and potentially exposed patients to unnecessary risk.' The study noted concerns in the medical profession about the impact on training and employment of resident doctors when PAs take on tasks. When it comes to the safety of PAs and AAs, Prof Leng said the 'evidence is poor', with 'no compelling evidence' in published research 'that PAs were safe to work as doctor substitutes in primary care'. She also said the evidence was poor when it came to cost effectiveness. The report said that while research suggests patients are satisfied after seeing a PA, some did not know they were not seeing a doctor. Many doctors also told the review they were concerned about the time required to supervise PAs and AAs and the lack of training for supervisors about the role of PAs. A survey conducted for the report found 'relatively few doctors felt it was appropriate for PAs to diagnose illness', with only 29% of those working with PAs in primary care backing this, and 14% in secondary care. The survey also found 'marked differences in which tasks were considered appropriate in primary and secondary care, with PAs significantly more likely than doctors to believe that certain activities were appropriate for them to carry out'. When it came to AAs, there were also questions over whether the role was actually needed as fully qualified anaesthetists already face tough competition to find a job. Prof Leng concluded there were 'no convincing reasons to abolish the roles of AA or PA' but there is also no case 'for continuing with the roles unchanged'. She recommended that both PAs and AAs should have the opportunity for ongoing training and development, with potential to prescribe medicines in the future, and they should also should have the opportunity to become an 'advanced' PA or AA. A named doctor should take overall responsibility for each PA, while clothing, lanyards, badges and staff information should be standardised to 'distinguish physician assistants from doctors'. Six patient deaths linked to contact with PAs have been recorded by coroners in England. One high-profile death involved Emily Chesterton, 30, who died from a pulmonary embolism. She was misdiagnosed by a PA on two occasions and told she had anxiety. Unison head of health, Helga Pile, said: 'By working closely with doctors and other healthcare professionals, these roles can make a real difference to the improvement of services and reduction of waiting lists. 'Clearer identification of physician associates and anaesthesia associates will give patients a greater understanding of who's delivering their care and what they can expect. ' Dr Tom Dolphin, chair of BMA council, said the review 'laid bare the catastrophic failures in NHS leadership that have put patients at serious risk of harm' but said its recommendations 'do not adequately protect patients'. He added: 'Despite correctly recommending that assistants shouldn't be the first person seeing patients coming straight through the doors in GP practices or in A&E, the report then contradicts itself by saying that PAs can act as a first point of contact in primary care for minor and common conditions. 'It is not clear how these two recommendations can coexist, and this must be urgently clarified. Minor complaints are only minor in retrospect and serious conditions can present in subtle or unusual ways. 'No doubt doctors will look back at this report as a moment when historic failures could have been addressed and patients finally protected – but sadly will see this as an inadequate response to what is a patient safety scandal.'
Newsweek
9 hours ago
- Newsweek
Men Are Gaining More Confidence From Ozempic Than Women: Report
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. While some may associate Ozempic and other GLP-1 medications with women trying to lose weight, it turns out that men are the ones gaining the most significant confidence boosts from it. In a Kinsey Institute and survey of GLP-1 users, men were three times more likely than women to say GLP-1s gave them more confidence. They also experienced more notable improvements in their dating lives and libidos. Why It Matters In recent years, the use of weight-loss medications called glucagon-like peptide-1 (GLP-1) receptor agonists has surged. Popular products include Ozempic, Mounjaro, Wegovy and Zephound and have been a game changer for many Americans who are obese or have type 2 diabetes. For patients who successfully lose weight, there can be significant changes in their mental health as well as their personal dating lives, but this impact appears to be more pronounced among male users. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Steve Christo - Corbis/Corbis via Getty Images What To Know Across the entire survey sample, drugs like Ozempic were having major effects on users' dating lives. While 59 percent of users said the drugs changed their dating experiences, men experienced a more notable impact on their confidence levels and sex lives, according to the report. Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and increased sexual activity. Still, there were some negative implications for men, of which 60 percent said they feared being judged for using GLP-1s and worried they'd be seen as "less masculine" for doing so. Of all GLP-1 users surveyed, 12 percent said they were going on more dates, and 14 percent said they were getting more matches on dating apps. Meanwhile, a whopping 52 percent reported changes in their sex lives. What People Are Saying Dr. Justin Lehmiller, the Kinsey Institute study lead, said in a statement: "I think there's a very nuanced story to tell here. How these drugs impact your sex life will depend on a variety of factors, including drug dosage and drug type, speed of weight loss, starting and ending weight, and how much you changed your health and fitness habits at the same time." "Sexually speaking, it appears that men are experiencing more positive and more negative impacts of GLP-1 medications." What Happens Next The long-term implications of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. GLP-1 medications are also associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea, and even stomach paralysis in rare cases.
